Trastuzumab has been approved for nearly a decade, but it is still unclear which women with early-stage disease might benefit most from treatment.
A retrospective analysis of crizotinib data demonstrates control in advanced, metastatic disease, although brain metastases continued to progress.
The "antigocoagulation gastrointestinal stress test" could represent a previously under-recognized modality leading to early detection of GI malignancy.
Toni K. Choueiri, MD, delivered a keynote lecture on recent advances in the treatment of renal cell carcinoma at the 2015 GU Symposium.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Body Mass Index Predicts Survival in Metastatic Clear Cell Renal Cell Carcinoma
- Renal Cell Cancer: Keynote Lecture From GU Symposium 2015
- Disease Progression of Mantle Cell Lymphoma After Ibrutinib Associated with Poor Outcome
- Paclitaxel, Trastuzumab New Standard of Care for Early-Stage Breast Cancer
- Short-Term ADT Does Not Improve Radiotherapy-Associated Survival in Prostate Cancer
- Anticoagulants and Gastrointestinal Cancer Detection
- In Breast Cancer, Goserelin Protects Against Ovarian Failure
- Soligenix to Enroll Additional Subjects in SGX942 Trial for Oral Mucositis
- Cytarabine Plus Amonafide L-Malate Shows Similar Efficacy in Leukemia to Daunorubicin
- Correlated Spectroscopy Can Identify Changes in BRCA Carriers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|